Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement GMP proposal "one-size-fits-all" approach is "naive," commenters maintain.

This article was originally published in The Tan Sheet

Executive Summary

SUPPLEMENT GMP PROPOSAL "ONE-SIZE-FITS-ALL" APPROACH "NAIVE" both technologically and scientifically, a group of joint commenters proclaim in May 7 comments to FDA on the Feb. 7 advance notice of proposed rulemaking suggesting Good Manufacturing Practices regulations for the dietary supplement industry ("The Tan Sheet" Feb. 10, p. 2). The one-size-fits-all approach of the ANPR -- i.e., the same regulatory oversight for companies that just fill capsules and those who grow botanicals and process them -- "is based on a faulty assumption that dietary supplements are, to a degree, fungible when they are extraordinarily diverse and are produced using vastly different techniques and methods of production," the commenters maintain.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS087049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel